Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2004
NET PRODUCT SALES DETAIL (millions of dollars)
- ----------------------------------------------
2Q `04 vs. 2Q `03
-----------------------------------------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG(1) $ % CHG(1) $ % CHG $
- -----------------------------------------------------------------------------------------------------------------------------------
AGGRASTAT -17% 21 * - 9% 21
ARCOXIA * 62 - - * 62
CANCIDAS 65% 101 64% 58 66% 43
COZAAR / HYZAAR 34% 725 70% 259 20% 466
CRIXIVAN / STOCRIN -21% 64 -75% 6 2% 58
EMEND -39% 9 -42% 8 * 1
FOSAMAX 45% 792 58% 438 32% 354
INVANZ 86% 16 69% 11 * 4
MAXALT 56% 79 87% 51 20% 28
PRIMAXIN 5% 153 12% 36 3% 117
PROPECIA 28% 65 54% 32 10% 33
PROSCAR 2% 185 -1% 95 6% 90
SINGULAIR 52% 643 67% 453 26% 189
TIMOPTIC / TIMOPTIC XE -10% 39 -60% 2 -2% 36
TRUSOPT / COSOPT 8% 133 12% 58 6% 75
VASOTEC / VASERETIC -3% 195 * - -5% 195
VIOXX -18% 653 -35% 357 20% 296
ZOCOR 12% 1,370 27% 958 -11% 411
HEPATITIS VACCINES -18% 43 -27% 31 22% 11
VIRAL VACCINES 1% 135 -1% 124 19% 11
OTHER VACCINES -9% 46 -13% 34 5% 12
* 100% or over
TOTAL SALES: VOLUME, PRICE, EXCHANGE
- ------------------------------------
2Q '04 % CHG. VOL PX FX
TOTAL PHARMACEUTICAL SALES $ 6,022 9% 5 1 3
------- -- - - -
U.S. ($ MM) 3,454 7% 4 3 0
Foreign ($ MM) 2,567 11% 7 -3 7
- ------------------------------------------------------------------------------------------------------------------------------------
(1) Sales growth for the quarter includes a favorable comparison to
2003, which was impacted by $405 million of wholesaler buy-out. Following the
implementation of the new distribution program for U.S. wholesalers in the
fourth quarter of 2003, fluctuations in 2004 sales caused by wholesaler
investment buying have significantly moderated.
Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
YEAR-TO-DATE
2004
NET PRODUCT SALES DETAIL (millions of dollars)
- ----------------------------------------------
JUNE YTD `04 vs. JUNE YTD `03
--------------------------------------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG $ % CHG $ % CHG $
- ------------------------------------------------------------------------------------------------------------------------------------
AGGRASTAT -10% 44 * - 12% 44
ARCOXIA * 92 - - * 92
CANCIDAS 75% 189 72% 107 79% 82
COZAAR / HYZAAR 15% 1,354 8% 475 20% 879
CRIXIVAN / STOCRIN -22% 129 -81% 12 14% 116
EMEND 4% 15 -2% 14 * 1
FOSAMAX 16% 1,551 4% 880 35% 671
INVANZ 94% 27 72% 20 * 8
MAXALT 5% 135 -6% 80 25% 54
PRIMAXIN -2% 303 -31% 65 11% 238
PROPECIA 10% 128 8% 61 12% 67
PROSCAR 15% 359 17% 178 14% 181
SINGULAIR 43% 1,266 46% 880 36% 385
TIMOPTIC / TIMOPTIC XE -3% 76 -34% 5 0% 71
TRUSOPT / COSOPT 16% 264 15% 110 17% 155
VASOTEC / VASERETIC 0% 367 * - -2% 367
VIOXX 0% 1,314 -13% 743 25% 571
ZOCOR 11% 2,665 33% 1,858 -19% 807
HEPATITIS VACCINES -12% 103 -14% 84 -3% 19
VIRAL VACCINES 0% 252 -2% 229 28% 23
OTHER VACCINES -10% 98 -14% 74 2% 24
* 100% or over
TOTAL SALES: VOLUME, PRICE, EXCHANGE
- ------------------------------------
YTD `04 % CHG. VOL PX FX
TOTAL PHARMACEUTICAL SALES $ 11,653 5% 0 1 4
--------- -- -- -- --
U.S. ($ MM) 6,710 1% -2 3 0
Foreign ($ MM) 4,943 11% 4 -3 10
- ---------------------------------------------------------------------------------------------------------------------------------
Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2004
===============================================================================
OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (millions of dollars)
----------------------------------------------------------------------------
2Q `04 2Q `03 YTD 2004 YTD 2003
--------------------------------------------------------------------------------------------------------------------------
INTEREST INCOME $ (68.5) $ (82.2) $ (134.2) $ (169.6)
INTEREST EXPENSE 71.6 94.6 144.4 189.9
EXCHANGE (GAINS)/LOSSES 14.9 (16.3) 7.1 (23.4)
MINORITY INTERESTS 36.8 40.6 76.4 92.4
AMORTIZATION OF INTANGIBLES 37.2 36.9 74.5 68.2
Other, net (22.1) (195.4) (339.1) (231.5)
-------------------------------------------------------
TOTAL $ 69.9 $(121.8) $ (170.9) $ (74.0)
--------------------------------------------------------------------------------------------------------------------------
=================================================================================================================================
JOINT VENTURE SALES DETAIL (MILLIONS OF DOLLARS)
------------------------------------------------
All sales reported here are end-market JV sales,
presented on a "NET" basis.
MERIAL 2Q `04 2Q `03 YTD 2004 YTD 2003
--------------------------------------------------------------------------------------------------------------------------
IVOMEC, HEARTGARD, other avermectins $ 103 $ 115 $ 197 $ 212
FRONTLINE 184 171 345 303
Biologicals 110 98 223 200
Other Animal Health 58 50 109 96
Poultry Breeding 36 37 71 75
-----------------------------------------------------
TOTAL MERIAL SALES $ 491 $ 470 $ 945 $ 887
--------------------------------------------------------------------------------------------------------------------------
AVENTIS PASTEUR-MSD 2Q `04 2Q `03 YTD 2004 YTD 2003
--------------------------------------------------------------------------------------------------------------------------
HEPATITIS VACCINES $ 21 $ 19 $ 41 $ 37
VIRAL VACCINES 14 13 27 24
Other Vaccines 125 114 245 204
-----------------------------------------------------
TOTAL AP-MSD SALES $ 159 $ 146 $ 313 $ 265
--------------------------------------------------------------------------------------------------------------------------
MERCK / SCHERING-PLOUGH COLLABORATION 2Q `04 2Q `03 YTD 2004 YTD 2003
--------------------------------------------------------------------------------------------------------------------------
VYTORIN (Worldwide) $ 5 $ - $ 5 $ -
ZETIA (Worldwide) 242 123 432 169
TOTAL $ 247 $ 123 $ 437 $ 169
--------------------------------------------------------------------------------------------------------------------------
==========================================================================================================================